|Articles|July 1, 2016

BioPharm International

  • BioPharm International-07-01-2016
  • Volume 29
  • Issue 7

Modular Bioreactor Simplifies Process Development

The ambr 250 mini benchtop bioreactor system from Sartorius Stedim Biotech can be used for parallel fermentation and cell culture.

The ambr 250 mini benchtop bioreactor system from Sartorius Stedim Biotech can be used for parallel fermentation and cell culture. The system combines a unique single-use bioreactor vessel and expandable system design for process development. The new ambr 250 modular system consists of a workstation with two, four, six, or eight single-use bioreactors, with a working volume range of 100-250 mL. These mini bioreactors, based on the same stirred tank bioreactors in the high throughput system, contain impellers suitable for fermentation or cell culture, and scale up to larger bioreactors. They are also fully integrated with liquid reservoirs and syringe pumps, allowing rapid experimental set up and turn around, thus significantly increasing lab efficiency. Once installed, the bioreactor has all the required process services for parameter control, including pH, DO, temperature, and agitation. Feeds can also be delivered from the reagent reservoirs via syringe pumps into the bioreactor. One control unit is capable of controlling up to eight bioreactor stations independently using a touch screen user interface.

Sartorius Stedim Biotech


Related to this article

The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.